Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid set to launch its évolis hair care products in the lucrative Chinese market

Bringing a unique and differentiated product range to the world's fastest-growing market.
evolis hair care products
5-year deal with minimum order requirements for each year

Cellmid Limited’s (ASX:CDY) wholly owned subsidiary Advangen has entered into an exclusive agreement to distribute its évolis® anti-aging hair care products in the Peoples Republic of China.

The company has signed a five-year agreement with Beijing Fukangren Bio-pharm Tech Co Ltd for the distribution of évolis lotions and shampoos.

The agreement between Advangen and Fukangren has two key stages:

• A 12-month period where, for and on behalf of Advangen, Fukangren will register the évolis lotions as hair loss products with the Chinese regulator, SFDA (State Food & Drug Administrator); and
• An exclusive distribution agreement for the évolis® lotions and shampoos for five years with minimum order requirements for each year.

READ: Cellmid's year-to-date sales exceed full-year sales for 2017 with further momentum expected

Shares were up almost 10% intra-day to 56.5 cents.

évolis is being launched in China following extensive market research regarding product demand, fit and pricing against comparable products within the Chinese market.

The first-in-class FGF5 inhibitor technology of évolis with natural active ingredients provides it with a unique marketing proposition and a significant competitive edge.

Adding further differentiation in the Chinese market is the highly desirable “Australian made” and “Japanese made” status of the évolis products.

Fukangren has the potential to make évolis a success in China

Beijing Fukangren, established in 2000, is a rapidly growing pharmaceutical company with over 400 staff, distributing over 300 products including generics and drugs under licence and profit arrangement.

Fukangren also has a specialist regulatory affairs team with a strong track record of successful applications with the Chinese regulator, SFDA.

Cellmid chief executive officer Maria Halasz said: “This agreement is an important step towards bringing évolis to the Chinese people, and we believe Fukangren has the resources, capacity and market know-how to make évolis a success in China.”

Chinese market opportunity

Three recent surveys of university students identified hair loss concerns among younger Chinese citizens, with 60-70% of respondents indicating that they were suffering from hair loss or had hair loss concerns.

Cellmid has a significant potential in China, given the magnitude of the country’s population and the size of its new middle class, estimated at over 100 million households with growing disposable income.

Halasz added: “The Chinese market is a key element of Cellmid’s growth strategy and we expect it will contribute significantly to growing our revenues in the coming years.”

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
1540445560_757z468_1537832469_knee.jpg
October 25 2018
The partnership with the US-based network will give Paradigm substantial exposure and access to a large patient pool.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use